Emer­gent says it has $400M in or­ders re­lat­ed to mpox out­break 

Emer­gent BioSo­lu­tions has se­cured around $400 mil­lion worth of or­ders for its small­pox and mon­key­pox prod­ucts, in­clud­ing its vac­cine be­ing used to help pro­tect against …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER